ESTRO 2023 | SKAGEN & HypoG-01 trials: hypofractionated RT in early breast cancer reduces arm lymphedema risk

Sofia Rivera, MD, PhD, Gustave Roussy, Villejuif, France, comments on the significance of the SKAGEN Trial 1 trial (NCT02384733) and the Phase III HypoG-01 trial (NCT03127995) of locoregional hypo vs normofractionated radiotherapy in early breast cancer. These two independent randomized trials provide strong evidence that moderately hypofractionated radiotherapy is noninferior to hypofractionated radiotherapy in terms of the risk of arm lymphedema. This significant finding marks a shift in practice, allowing for the implementation of hypofractionated radiotherapy in patients requiring regional irradiation for breast cancer. This change not only reduces the number of radiotherapy sessions for patients but also decreases the resource requirements for radiotherapy departments. Overall, these trials have a major impact on both patients and healthcare professionals involved in breast cancer treatment. This interview took place at the ESTRO congress in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.